Liège, Belgium, November 25, 2022 – 18:55 CET – Mithra (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, notes the market reaction following the evolution of the Company’s share price, but reaffirms its strategic intentions related to its product-candidate Donesta®. The Company therefore maintains the operational calendar as announced in the half-year results of September 23rd.
Negotiations with potential partners to commercialize the Donesta® product candidate are ongoing. The objective of announcing binding offers at the end of the year is maintained. The receipt of the first safety data from the phase 3 Donesta® study conducted in the United States and Canada is expected by the end of 2022.